This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: glucose

News from the Cardiorenal Forum 9th Annual Scientific Meeting – embracing the future, not forgetting the past

March 2015 Br J Cardiol 2015;22:17

News from the Cardiorenal Forum 9th Annual Scientific Meeting – embracing the future, not forgetting the past

Dr Legate Philip

Abstract

Managing risk factors – the old offenders Diet An update on diet and cardiovascular disease was given by Professor Kay Tee Khaw (University of Cambridge). A surprise recent finding has been that increased body mass index (BMI) trends do not directly correlate with cardiovascular mortality, particularly in Mediterranean countries (figure 1). Figure 1. Body mass index and associated coronary heart disease in Europe. Panel a) body mass index; panel b) coronary heart disease This gives rise to the question: is diet a key moderating factor in the relationship between BMI and cardiovascular mortality? The PREDIMED (Effects of the Mediterranean Di

| Full text
What is the best blood sugar level in diabetics? –New UK data

March 2010 Br J Cardiol 2010;17:59-61

What is the best blood sugar level in diabetics? –New UK data

BJ Cardio Staff

Abstract

These findings are in line with those of the US ACCORD trial which was stopped early because of an increased risk of death in type 2 diabetes patients who underwent intensive blood glucose lowering compared with conventional therapy. In the new UK study, published recently in The Lancet (Lancet 2010;375:481–9), the lowest death and event rates were seen at an HbA1c level of 7.5%. The new data come from studying around 48,000 type 2 diabetes patients aged 50 or over who are included in the UK General Practice Research Database. These patients had either had their treatment intensified from oral monotherapy to combination therapy with oral bl

| Full text

July 2008 Br J Cardiol 2008;15:185-88

News

BJCardio editorial team

Abstract

New data on intensive glucose lowering in type 2 diabetes The results of three large trials investigating the clinical effects of intensive glucose lowering in patients with type II diabetes were presented at the recent American Diabetes Association meeting in San Francisco, USA, and have shown somewhat conflicting results. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial was stopped earlier this year because of an increased mortality in the intensive glucose lowering group. The two other trials – ADVANCE (Action in Diabetes and Vascular Disease – Preterax and Diamicron MR Controlled Evaluation) and VADT (Veteran’s A

| Full text

March 2008 Br J Cardiol 2008;15:68-9

Questions raised on very intensive glucose lowering in type 2 diabetes

BJCardio editorial team

Abstract

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, conducted by the US National Heart, Lung, and Blood Institute (NHLBI), was stopped in February because the group being treated with intensive glucose lowering was showing a higher mortality rate than the group receiving standard treatment. But just days later, the group organising another similar trial, ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), announced that preliminary results of their study did not confirm the adverse mortality trend with intensive treatment reported from the ACCORD study.

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now